IRLAB Therapeutics
1.59 SEK
+0.89 %
Less than 1K followers
IRLAB A
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for IRLAB Therapeutics
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.0 | 42.8 | 94.6 | 4.4 | 19.5 | 18.9 | 14.7 | 57.5 |
| EBITDA | -28.2 | -1.9 | -70.5 | -27.5 | -24.6 | -16.1 | -20.8 | -89.1 |
| EBIT | -29.4 | -3.0 | -75.1 | -28.6 | -25.7 | -17.2 | -21.9 | -93.4 |
| EBIT-% | -325.2 % | -7.0 % | -79.4 % | -656.9 % | -131.7 % | -91.1 % | -148.5 % | -162.5 % |
| Profit before taxes | -31.7 | -5.4 | -83.1 | -34.0 | -32.3 | -20.2 | -23.5 | -110.0 |
| Net income | -31.7 | -5.4 | -83.1 | -34.0 | -32.3 | -20.2 | -23.5 | -110.0 |